Literature DB >> 17346134

Reduction of anti-HIV-1 Gag immune responses during co-immunization: immune interference by the HIV-1 envelope.

Franklin R Toapanta1, Jodi K Craigo, Ronald C Montelaro, Ted M Ross.   

Abstract

Immunization with more than one immunogen (co-immunization) is an efficient regimen to induce immunity to multiple antigens. However, immune interference has been reported using multi-plasmid DNA immunizations. HIV-1 envelope (Env) and Gag gene products are the predominant immunogens used in current AIDS vaccines, although, few studies have evaluated possible immune interference when these two antigens are co-administered. Therefore, in this study, immune interference during co-inoculation was examined using DNA vaccines expressing lentiviral Envs and Gag from gene sequences optimized for efficient expression in mammalian cells (codon-optimized). BALB/c mice vaccinated in separate hind legs with each plasmid individually elicited high titer immune responses, however, when HIV-1 Env(gp120) and HIV-1 Gag(p55) DNA plasmids were co-inoculated, there was a reduction in the immune responses elicited to HIV-1 Gag(p55). To determine if the anti-HIV-1 Gag(p55) immune interference was specific to HIV-1 Env(gp120), mice were co-immunized with plasmids expressing the surface envelope protein from two additional lentiviruses, Env(gp130)-SIV or Env(gp90)-EIAV, or a soluble form of hemagglutinin (sHA) from influenza virus and HIV-1 Gag(p55)- or SIV Gag(p55)-DNA. Interestingly, there was no reduction in anti-HIV-1 Gag(p55) immune responses using other lentiviral envelopes or the influenza sHA. Also, none of the lentiviral envelopes reduced anti-SIV Gag(p55) immune responses during co-immunization. Therefore, anti-HIV-1 Gag immune interference appears specific to co-immunizations with HIV-1 Env(gp120) and may involve a yet undefined immunological mechanism(s).

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17346134     DOI: 10.2174/157016207780077057

Source DB:  PubMed          Journal:  Curr HIV Res        ISSN: 1570-162X            Impact factor:   1.581


  19 in total

1.  Evaluation of humoral, mucosal, and cellular immune responses following co-immunization of HIV-1 Gag and Env proteins expressed by Newcastle disease virus.

Authors:  Sunil K Khattar; Senthilkumar Palaniyandi; Sweety Samal; Celia C LaBranche; David C Montefiori; Xiaoping Zhu; Siba K Samal
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

Review 2.  Env Exceptionalism: Why Are HIV-1 Env Glycoproteins Atypical Immunogens?

Authors:  P J Klasse; Gabriel Ozorowski; Rogier W Sanders; John P Moore
Journal:  Cell Host Microbe       Date:  2020-04-08       Impact factor: 21.023

3.  Combination Adenovirus and Protein Vaccines Prevent Infection or Reduce Viral Burden after Heterologous Clade C Simian-Human Immunodeficiency Virus Mucosal Challenge.

Authors:  Delphine C Malherbe; Jason Mendy; Lo Vang; Philip T Barnette; Jason Reed; Samir K Lakhashe; Joshua Owuor; Johannes S Gach; Alfred W Legasse; Michael K Axthelm; Celia C LaBranche; David Montefiori; Donald N Forthal; Byung Park; James M Wilson; James H McLinden; Jinhua Xiang; Jack T Stapleton; Jonah B Sacha; Barton F Haynes; Hua-Xin Liao; Ruth M Ruprecht; Jonathan Smith; Marc Gurwith; Nancy L Haigwood; Jeff Alexander
Journal:  J Virol       Date:  2018-01-02       Impact factor: 5.103

4.  Occluding the mannose moieties on human immunodeficiency virus type 1 gp120 with griffithsin improves the antibody responses to both proteins in mice.

Authors:  Kaustuv Banerjee; Elizabeth Michael; Dirk Eggink; Thijs van Montfort; Amanda B Lasnik; Kenneth E Palmer; Rogier W Sanders; John P Moore; Per Johan Klasse
Journal:  AIDS Res Hum Retroviruses       Date:  2011-07-27       Impact factor: 2.205

5.  Impact of antibody quality and anamnestic response on viremia control post-challenge in a combined Tat/Env vaccine regimen in rhesus macaques.

Authors:  Thorsten Demberg; Egidio Brocca-Cofano; Seraphin Kuate; Stanley Aladi; Diego A Vargas-Inchaustegui; David Venzon; Irene Kalisz; V S Kalyanaraman; Eun Mi Lee; Ranajit Pal; Janet DiPasquale; Ruth M Ruprecht; David C Montefiori; Indresh Srivastava; Susan W Barnett; Marjorie Robert-Guroff
Journal:  Virology       Date:  2013-03-22       Impact factor: 3.616

6.  X4 human immunodeficiency virus type 1 gp120 down-modulates expression and immunogenicity of codelivered antigens.

Authors:  Avi-Hai Hovav; Michael Santosuosso; Maytal Bivas-Benita; Andre Plair; Alex Cheng; Mazal Elnekave; Elda Righi; Tao Chen; Satoshi Kashiwagi; Michael W Panas; Shi-Hua Xiang; Karina Furmanov; Norman L Letvin; Mark C Poznansky
Journal:  J Virol       Date:  2009-08-19       Impact factor: 5.103

7.  The efficacy of T cell-mediated immune responses is reduced by the envelope protein of the chimeric HIV-1/SIV-KB9 virus in vivo.

Authors:  Liljana Stevceva; Victor Yoon; Angela Carville; Beatriz Pacheco; Michael Santosuosso; Birgit Korioth-Schmitz; Keith Mansfield; Mark C Poznansky
Journal:  J Immunol       Date:  2008-10-15       Impact factor: 5.422

8.  A phase I double blind, placebo-controlled, randomized study of a multigenic HIV-1 adenovirus subtype 35 vector vaccine in healthy uninfected adults.

Authors:  Michael C Keefer; Jill Gilmour; Peter Hayes; Dilbinder Gill; Jakub Kopycinski; Hannah Cheeseman; Michelle Cashin-Cox; Marloes Naarding; Lorna Clark; Natalia Fernandez; Catherine A Bunce; Christine M Hay; Sabrina Welsh; Wendy Komaroff; Lottie Hachaambwa; Tony Tarragona-Fiol; Eddy Sayeed; Devika Zachariah; James Ackland; Kelley Loughran; Burc Barin; Emmanuel Cormier; Josephine H Cox; Patricia Fast; Jean-Louis Excler
Journal:  PLoS One       Date:  2012-08-03       Impact factor: 3.240

9.  Altering an artificial Gagpolnef polyprotein and mode of ENV co-administration affects the immunogenicity of a clade C HIV DNA vaccine.

Authors:  Katharina Böckl; Jens Wild; Simon Bredl; Kathrin Kindsmüller; Josef Köstler; Ralf Wagner
Journal:  PLoS One       Date:  2012-04-11       Impact factor: 3.240

10.  Clinical adjuvant combinations stimulate potent B-cell responses in vitro by activating dermal dendritic cells.

Authors:  Katie Matthews; Nancy P Y Chung; Per Johan Klasse; Magda Moutaftsi; Darrick Carter; André M Salazar; Steven G Reed; Rogier W Sanders; John P Moore
Journal:  PLoS One       Date:  2013-05-20       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.